Abstract
A number of studies report the incidence of Alzheimer’s disease (AD) in patients taking statins, but the results are inconsistent. (1) Background: The present study investigated the cross-sectional association between previous statin use and the risk of AD development in Korean residents. (2) Methods: We used the Korean National Health Insurance Service-National Sample Cohort; 17,172 AD patients were matched by age, gender, income, and region of residence with 68,688 control participants at a ratio of 1:4. We used a multiple conditional logistic regression model to analyse the association between the number of days of statin use and AD occurrence. Further analyses were performed to identify whether this association is maintained for different ages, genders, socioeconomic status groups, and covariates. (3) Results: The odds ratio, which was adjusted for potential confounders, for the days of statin use per year in the AD group compared to the control group was 0.95 (95% confidence interval = 0.92–0.98; p = 0.003). The number of days of statin use in the AD group was significantly smaller in the subgroups of non-smokers and individuals with normal weight, alcohol consumption less than once a week, total cholesterol level below 200 mg/dL, systolic blood pressure below 140, diastolic blood pressure below 90, and fasting blood glucose below 100 mg/dL. (4) Conclusions: Our results suggest that statin use prevents the occurrence of AD. The effects of statin use in preventing AD may be greater in individuals at relatively low risk.
Highlights
Alzheimer’s disease (AD) is the most common form of dementia and the most common cause of neurodegenerative dementia in elderly individuals, accounting for approximately 60% or more of all individuals with dementia [1]
(3) Results: The odds ratio, which was adjusted for potential confounders, for the days of statin use per year in the AD group compared to the control group was 0.95 (95% confidence interval = 0.92–0.98; p = 0.003)
The number of days of statin use in the AD group was significantly smaller in the subgroups of non-smokers and individuals with normal weight, alcohol consumption less than once a week, total cholesterol level below 200 mg/dL, systolic blood pressure below 140, diastolic blood pressure below 90, and fasting blood glucose below 100 mg/dL. (4) Conclusions: Our results suggest that statin use prevents the occurrence of AD
Summary
Alzheimer’s disease (AD) is the most common form of dementia and the most common cause of neurodegenerative dementia in elderly individuals, accounting for approximately 60% or more of all individuals with dementia [1]. Over 50 million people worldwide are living with dementia, and the number of patients affected is expected to rise to 152 million by 2050 [2]. This rapidly increasing disease burden is challenging healthcare and socioeconomic systems worldwide. Among all causes of dementia, vascular dementia is more likely to benefit from statins use because it shares the same risk factors as ischemic stroke, and elevated levels of serum total cholesterol and LDL and decreased levels of high-density lipoprotein (HDL) are associated with the risk of vascular dementia [13]. We assessed whether these associations are consistent for different groups in a subgroup analysis stratified by age, gender, socioeconomic factors such as income and region of residence, and baseline medical comorbidities including dyslipidaemia, total cholesterol, obesity, smoking status, alcohol consumption, blood pressure, and fasting blood glucose
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
